Shuttle Pharmaceuticals ... (SHPH)
0.86
-0.04 (-4.43%)
At close: Jan 14, 2025, 3:58 PM
0.85
-1.24%
Pre-market Jan 15, 2025, 04:22 AM EST
undefined% (undefined)
| Bid | 0.85 |
| Market Cap | 3.15M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -4.25 |
| PE Ratio (ttm) | -0.2 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 0.91 |
| Volume | 52,021 |
| Avg. Volume (20D) | 1,164,808 |
| Open | 0.92 |
| Previous Close | 0.90 |
| Day's Range | 0.83 - 0.93 |
| 52-Week Range | 0.58 - 4.94 |
| Beta | undefined |
About SHPH
Shuttle Pharmaceuticals Holdings, Inc., through its subsidiary, Shuttle Pharmaceuticals, Inc., focuses on the discovery, development, and commercialization of drugs for sensitizing cancers to radiation therapy. Its products in clinical stage include Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and soft tissue sarcomas; and Doranidazole, an injectable hypoxic cell radiation sensitizer for treatment of pancreat...
Sector Healthcare
IPO Date Aug 31, 2022
Employees 8
Stock Exchange NASDAQ
Ticker Symbol SHPH
Website https://www.shuttlepharma.com
2 months ago ·
Source
+35.34%
Shuttle Pharmaceuticals shares are trading higher ...
Unlock content with
Pro Subscription
2 months ago ·
Source
+35.34%
Shuttle Pharmaceuticals shares are trading higher after the company announced it finalized agreements with all six of the planned site enrollment locations to administer the Phase 2 clinical trial of Ropidoxuridine.
